Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A minnie pearl cancer research network study

Journal of Clinical Oncology

Volumn 24, Issue 22, 2006, Pages 3548-3554

  Hainsworth, John D ^a   Spigel, David R ^a   Litchy, Sharlene ^a   Anthony Greco, F ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RESEARCH; CANCER SURVIVAL; CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE DISEASE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; VOMITING; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NEUROENDOCRINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33747061873     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.0575     Document Type: Article

References (30)

1. Choong NWW, Quevedo JF, Kaur JS: Small cell carcinoma of the urinary bladder: The Mayo Clinic experience. Cancer 103:1172-1178, 2005
2. Papandreau CN, Daliani DD, Thall PF, et al: Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072-3080, 2002
3. Hoskins PJ, Swenerton KD, Pike JA, et al: Small-cell carcinoma of the cervix: Fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol 21:3495-3501, 2003
4. Van der Gaast A, Verwey J, Prins E, et al: Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas. Cancer 65:422-424, 1990
5. Mills SE, Cooper PH, Garland TA, et al: Small cell undifferentiated carcinoma of the larynx: Report of two patients and review of 13 additional cases. Cancer 51:116-120, 1983
6. Majhail NS, Elson P, Bukowski RM: Therapy and outcome of small cell carcinoma of the kidney: Report of two cases and a systematic review of the literature. Cancer 97:1436-1441, 2003
7. Brenner B, Tang LH, Klimstra DS, et al: Small-cell carcinomas of the gastrointestinal tract: A review. J Clin Oncol 22:2730-2739, 2004
8. Okuyama T, Korenaga D, Tamura S, et al: The effectiveness of chemotherapy with cisplatin and 5-fluorouracil for recurrent small cell neuroendocrine carcinoma of the rectum: Report of a case. Surg Today 29:165-169, 1999
9. Kelsen DP, Weston E, Kurtz R, et al: Small-cell carcinoma of the esophagus: Treatment by chemotherapy alone. Cancer 45:1558-1561, 1980
10. Tanabe G, Kajisa T, Shimazu H, et al: Effective chemotherapy for small cell carcinoma of the esophagus. Cancer 60:2613-2616, 1987
11. Yalan S, Ozsik Y, Tekuzman G: Metastatic small-cell carcinoma of the rectum responding dramatically to combination chemotherapy. Am J Clin Oncol 21:75-76, 1998
12. Hainsworth JD, Johnson DH, Greco FA: Poorly differentiated neuroendocrine carcinoma of unknown primary site: A newly recognized clinicopathologic entity. Ann Intern Med 109:364-372, 1988
13. Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995
14. Hesketh PJ, Crowley JJ, Burris HA, et al: Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group phase II trial. Cancer J Sci Am 5:237-241, 1999
15. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
16. Schiller JH, Kim K, Hutson P, et al: Phase II study of topotecan in patients with extensive stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial (E 1592). J Clin Oncol 14:2345-2352, 1996
17. Eisenhauer E, Gregg R, Ayoub J, et al: Gemcitabine: An active new agent in patients with previously untreated small cell lung cancer: A phase II trial of the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 12:330, 1993 (abstr)
18. Hainsworth JD, Gray JR, Stroup SL, et al: Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose intensities. J Clin Oncol 15:3464-3470, 1997
19. Einhorn L, Crawford J, Birch R, et al: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited stage small-cell lung cancer. J Clin Oncol 6:451-456, 1988
20. Sculier JP, Paesmans M, Bureau G, et al: Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small cell lung cancer. J Clin Oncol 14:2337-2344, 1996
21. Hainsworth JD, Erland JB, Kalman LA, et al: Carcinoma of unknown primary site: Treatment with one-hour paclitaxel, carboplatin, and extended schedule etoposide. J Clin Oncol 15:2385-2394, 1997
22. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
23. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Mitry E, Baudin E, Ducreux M, et al: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351-1355, 1999
25. Fjallskog M, Granberg D, et al: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101-1107, 2001
26. Pujol JL, Daures JP, Riviere A, et al: Etoposide plus cisplatin with or without the combination of 4-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 93:300-308, 2001
27. Neill HB, Herndon JE, Miller AA, et al: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. J Clin Oncol 23:3752-3759, 2005
28. Paccagnella A, Oniga F, Bearz A, et al: Paclitaxel/carboplatin vs. paclitaxel/carboplatin/gemcitabine in advanced NSCLC: Final results of a phase II-III multicentre study. Ann Oncol 15:181, 2004(suppl 3; abstr 687p)
29. Laack E, Dickgreber N, Muller T, et al: Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small cell lung cancer: From the German and Swiss Lung Cancer Study Group. J Clin Oncol 22:2348-2356, 2004
30. Kuzur ME, Shipley DL, Spigel DR, et al: Paclitaxel, carboplatin, and gemcitabine (PCG) versus gemcitabine and vinorelbine (GV) in chemotherapy naïve patients with advanced non-small cell lung cancer: A phase III trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 23:634s, 2005 (abstr 7056)